<DOC>
	<DOCNO>NCT00635310</DOCNO>
	<brief_summary>Percutaneous liver biopsy ( PLB ) gold standard grade necroinflammation stag fibrosis patient chronic viral hepatitis . Whether use 1-deamino-8-D-arginine vasopressin ( DDAVP ) PLBs hemodialysis ( HD ) patient chronic viral hepatitis comparable safety profile normal renal function ( NRF ) evaluate prospective study .</brief_summary>
	<brief_title>Safety Profiles Liver Biopsy Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin</brief_title>
	<detailed_description>Chronic viral hepatitis common dialysis patient , report prevalence annual incidence 3-80 % 2.9 % , respectively . Currently , percutaneous liver biopsy ( PLB ) remain gold standard grade necroinflammation stag fibrosis patient liver disease . In addition , liver histology help clinician determine eligibility renal transplantation , prognosis , necessity antiviral therapy dialysis patient chronic viral hepatitis . In chronic hepatitis patient normal renal function ( NRF ) , risks fatal non-fatal hemorrhage liver biopsies non-malignant disease 0.04 % 0.16 % , respectively . However , relative risk post-biopsy hemorrhage CHC patient end-stage renal disease NRF remain dispute . Deamino-8-D-arginine vasopressin ( DDAVP ) , synthetic analogue vasopressin , commonly use hemostatic agent treat uremic bleeding induce release von Willebrand factor ( vWF ) factor VIII storage sit endothelial cells.Previous study show one dose 0.3-0.4Î¼g/kg body weight DDAVP infusion dialysis patient could normalize bleeding time ( BT ) , prevent surgical renal biopsy bleeding . Nevertheless , two recent study show divergent liver biopsy-related bleeding complication rate ( 0 % 6 % , respectively ) dialysis CHC patient pre-treated DDAVP . Since study evaluate safety PLB CHC patient dialysis small retrospective nature , control biopsy route , type biopsy needle , use ultrasound guidance , number pass , study urgently need solve important issue . Thus , aim conduct large clinical trial compare safety profile PLB CHC patient hemodialysis ( HD ) pretreated DDAVP NRF biopsy technique .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Chronic hepatitis C ( presence antiHCV serum HCV RNA &gt; 6 month ) Chronic hepatitis B ( presence HBsAg &gt; 6 month ) Receiving regular hemodialysis normal renal function ( Creatinine &lt; 1.5 x ULN ) Receiving percutaneous liver biopsy ( PLB ) Human immunodeficiency virus ( HIV ) coinfection Unwilling contraindicate receive percutaneous liver biopsy ( PLB ) Receiving liver biopsy without ultrasound ( US ) guidance automatic cutting needle Did receive 2 pass liver biopsy Inadequate record postbiopsy complication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Liver biopsy</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>1-Deamino-8- D-Arginine Vasopressin</keyword>
</DOC>